Novartis announces FDA approval of MET inhibitor Tabrecta (capmatinib)for metastatic non-small cell lung cancer with METex14
Novartis has announced that the US Food and Drug Administration (FDA) approved…
MenQuadfi is Sanofi’s Latest vaccine for the prevention of invasive meningococcal disease (MenACWY)
MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate is a new Vaccine for the…
Tukysa (tucatinib) new option of treatment of adult patients with advanced forms of HER2-positive breast cancer
As part of Project Orbis, the U.S. Food and Drug Administration has approved…
Koselugo (selumetinib), newly approved treatment of neurofibromatosis type 1 (NF1)
The FDA has approved Koselugo (selumetinib) for the treatment of pediatric…
Sarclisa (isatuximab-irfc), new Therapy for Patients with Previously Treated Multiple Myeloma
The FDA has approved Sarclisa (isatuximab-irfc), in combination with…
Ofatumumab, the new potential first-choice treatment for Relapsing forms of Multiple Sclerosis
Novartis has announced that both the US Food and Drug Administration (FDA) and…
FDA Authorizes Marketing of the First Genetic Test to Aid in the Diagnosis of Fragile X Syndrome
The U.S. Food and Drug Administration has authorized marketing of the first…
FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma
Kite, a Gilead Company has announced that the U.S. Food and Drug Administration…
First Cardiac Ultrasound Software That Uses Artificial Intelligence to Guide User
The FDA has authorized marketing of software to assist medical professionals in…
Givlaari (givosiran), first treatment for acute hepatic porphyria
The EU Medicines Agency has recommended granting a marketing authorisation in…